Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

COMPUGROUP MEDICAL SE & CO. KGAA

(COP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CompuGroup Medical SE & Co. KGaA: Release of a capital market information

11/25/2021 | 03:14pm EST

DGAP Post-admission Duties announcement: CompuGroup Medical SE & Co. KGaA / Launch of the Share Buy-Back Program
CompuGroup Medical SE & Co. KGaA: Release of a capital market information

25.11.2021 / 21:12
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Disclosure pursuant to Article 5(1)(a) of Regulation (EU) No 596/2014 and Article 3(1) of Commission Delegated Regulation (EU) No 2016/1052

Launch of the Share Buy-Back Program

Koblenz, November 25, 2021 - The share buy-back program announced by CompuGroup Medical SE & Co. KGaA (the "Company") in the ad-hoc release of November 25, 2021 will be launched on November 26, 2021. The Company is making use of the authorization granted by the annual general meeting of May 19, 2021 to purchase treasury shares pursuant to section 71(1) no. 8 of the German Stock Corporation Act (Aktiengesetz) in order to buy back a maximum number of up to 500,000 shares of the Company (corresponding to approx. 0,93% of the Company's share capital) at a maximum purchase price (excluding transaction costs) of up to EUR 37,000,000.00 in total (the "Share Buy-Back Program").

The Share Buy-Back Program will be carried out by a credit institution. The credit institution will acquire the shares on the stock market and will decide on the timing of acquisitions independently of the Company and in accordance with the safe harbor provisions of Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (Market Abuse Regulation) in conjunction with the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. In addition, the consideration paid per share (excluding transaction costs) must not exceed, or fall short of, the price of the Company's shares in XETRA (or a comparable successor system) trading on the Frankfurt Stock Exchange determined by the opening auction on the trading day by more than 10%.

The acquired treasury shares in the Company may be used for any purpose permitted under the authorization granted by the annual general meeting of May 19, 2021, in particular for servicing the stock option plans or as consideration in the context of an acquisition.

The share buy-back via XETRA on the Frankfurt Stock Exchange will begin on November 26, 2021, 00:00 hrs (CET) and terminates at the end of January 27, 2022, 24:00 hrs (CET). In particular in case shares in the Company shall be bought back during a closed period within the meaning of Article 19(11) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014 or during a period in which the Company resolved to delay the disclosure of inside information in accordance with Article 17(4) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, the Company has appointed a credit institution for the execution of these buy-backs, which will make its decisions concerning the timing of the acquisitions of the shares in the Company - in compliance with contractual obligations - independently of, and without influence by, the Company in accordance with Article 4(2)(b) of Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The Company will not influence the decisions of the credit institution in this respect.

The Share Buy-Back Program will be carried out in accordance with the "safe harbor" provision pursuant to Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016 and on the basis of the aforementioned authorization of the general meeting of CompuGroup Medical SE & Co. KGaA of May 19, 2021. The Company also imposed corresponding obligations on the credit institution appointed by the Company for purchasing shares in the Company.

The shares in the Company will be purchased at market prices in accordance with the conditions for trading pursuant to Article 3 of Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016. In particular, the shares in the Company will not be purchased at a price higher than the higher of the price of the last independent trade or the highest current independent purchase bid on the trading venue where the purchase is carried out. In addition, the Company will not purchase on any trading day more than 25% of the average daily volume of the shares on the trading venue on which the purchase is carried out. The average daily volume of shares is calculated on the basis of the average daily volume traded during the 20 trading days preceding the relevant date of purchase.

The Share Buy-Back Program may be suspended and also resumed at any time, to the extent necessary and permitted by law.

Information on transactions relating to the Share Buy-Back Program will be adequately disclosed no later than by the end of the seventh trading day following the date of execution of such transactions in a detailed form and in an aggregated form. In addition, the Company will post the disclosed transactions on its website (www.cgm.com) and ensure that the information is kept available to the public for at least five years from the date of disclosure.

End

Disclaimer:

This publication contains forward-looking statements. These statements are based on the current views, expectations and assumptions of, and information available to, the management of CompuGroup Medical SE & Co. KGaA. Forward-looking statements do not provide a guarantee of the occurrence of future results and developments and involve known and unknown risks and uncertainties. Various factors may cause actual future results, developments or events to differ materially from those described in these statements. Neither CompuGroup Medical SE & Co. KGaA nor any other person assumes any responsibility whatsoever for the accuracy of the views expressed in this publication or the assumptions on which they are based. CompuGroup Medical SE & Co. KGaA assumes no obligation to update the forward-looking statements contained in this publication.

Koblenz, November 25, 2021

CompuGroup Medical SE & Co. KGaA
The general partner



25.11.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Internet: www.cgm.com

 
End of News DGAP News Service

1252106  25.11.2021 

fncls.ssp?fn=show_t_gif&application_id=1252106&application_name=news&site_id=zonebourse_sftp

ę EQS 2021
All news about COMPUGROUP MEDICAL SE & CO. KGAA
01/20COMPUGROUP MEDICAL SE & CO. KGAA : Notification and public disclosure of transactions by p..
EQ
01/19COMPUGROUP MEDICAL : Berenberg reaffirms its Buy rating
MD
01/18COMPUGROUP MEDICAL : Buy rating from Baader Bank
MD
01/18CompuGroup Medical expects continued strong organic growth in 2022 and first step towar..
EQ
01/18CompuGroup Medical SE & Co. KGaA Announces Delay in Publication of the Preliminary Resu..
CI
01/18CompuGroup Medical SE & Co. KGaA Provides Revenue Guidance for the Fiscal Year 2021 and..
CI
01/14COMPUGROUP MEDICAL : Kepler Cheuvreux gives a Buy rating
MD
01/11COMPUGROUP MEDICAL : Raised from Sell to Buy by Baader Bank
MD
01/10COMPUGROUP MEDICAL SE & CO. KGAA : Share Buy-Back Program - 6th Interim Announcement, conc..
EQ
01/03COMPUGROUP MEDICAL SE & CO. KGAA : Share Buy-Back Program - 5th Interim Announcement
EQ
More news
Analyst Recommendations on COMPUGROUP MEDICAL SE & CO. KGAA
More recommendations
Financials
Sales 2021 1 022 M 1 159 M 1 159 M
Net income 2021 79,2 M 89,8 M 89,8 M
Net Debt 2021 535 M 607 M 607 M
P/E ratio 2021 40,0x
Yield 2021 0,85%
Capitalization 3 119 M 3 538 M 3 537 M
EV / Sales 2021 3,58x
EV / Sales 2022 3,29x
Nbr of Employees 8 079
Free-Float 48,8%
Chart COMPUGROUP MEDICAL SE & CO. KGAA
Duration : Period :
CompuGroup Medical SE & Co. KGaA Technical Analysis Chart | COP | DE000A288904 | MarketScreener
Technical analysis trends COMPUGROUP MEDICAL SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 59,25 €
Average target price 84,25 €
Spread / Average Target 42,2%
EPS Revisions
Managers and Directors
Dirk W÷ssner Chairman-Management Board & CEO
Philipp von Ilberg Chairman-Supervisory Board
Frank Brecher Chief Technology Officer
Sven Thomas MŘller Chief Information Officer
Ulrike Handel Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
COMPUGROUP MEDICAL SE & CO. KGAA-16.73%3 538
ORACLE CORPORATION-5.72%219 564
SAP SE-2.96%162 147
SERVICENOW, INC.-21.78%101 038
CONSTELLATION SOFTWARE INC.-12.12%34 889
DOCUSIGN, INC.-23.75%22 979